{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:57:27Z","timestamp":1793825847833,"version":"4.6.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010686","name":"H2020 European Institute of Innovation and Technology","doi-asserted-by":"publisher","award":["633190"],"award-info":[{"award-number":["633190"]}],"id":[{"id":"10.13039\/100010686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","award":["FAIR-ALSII"],"award-info":[{"award-number":["FAIR-ALSII"]}],"id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00702-019-02138-1","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T14:24:35Z","timestamp":1580739875000},"page":"189-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"127","author":[{"name":"The FAIRPARK-II and FAIRALS-II studygroups","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Devos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Ioav","family":"Cabantchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Danel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mahoney-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Bouchaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore","family":"Gouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Duce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Devedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"key":"2138_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/brain\/aww278","volume":"140","author":"J Acosta-Cabronero","year":"2017","unstructured":"Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ et al (2017) The whole-brain pattern of magnetic susceptibility perturbations in Parkinson\u2019s disease. Brain 140:118\u2013131. https:\/\/doi.org\/10.1093\/brain\/aww278","journal-title":"Brain"},{"key":"2138_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jon.12127","volume":"25","author":"Y Adachi","year":"2015","unstructured":"Adachi Y, Sato N, Saito Y et al (2015) Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis: usefulness of SWI for the diagnoses of ALS. J Neuroimaging 25:443\u2013451. https:\/\/doi.org\/10.1111\/jon.12127","journal-title":"J Neuroimaging"},{"key":"2138_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10072-013-1595-2","volume":"35","author":"D Aquino","year":"2014","unstructured":"Aquino D, Contarino V, Albanese A et al (2014) Substantia nigra in Parkinson\u2019s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 35:753\u2013758. https:\/\/doi.org\/10.1007\/s10072-013-1595-2","journal-title":"Neurol Sci"},{"key":"2138_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ana.23817","volume":"73","author":"S Ayton","year":"2013","unstructured":"Ayton S, Lei P, Duce JA et al (2013) Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease: ceruloplasmin in PD. Ann Neurol 73:554\u2013559. https:\/\/doi.org\/10.1002\/ana.23817","journal-title":"Ann Neurol"},{"key":"2138_CR5","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1523\/JNEUROSCI.3439-14.2015","volume":"35","author":"S Ayton","year":"2015","unstructured":"Ayton S, Lei P, Hare DJ et al (2015) Parkinson\u2019s disease iron deposition caused by nitric oxide-induced loss of -Amyloid precursor protein. J Neurosci 35:3591\u20133597. https:\/\/doi.org\/10.1523\/JNEUROSCI.3439-14.2015","journal-title":"J Neurosci"},{"key":"2138_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-015-0055-2","volume":"10","author":"M Barbariga","year":"2015","unstructured":"Barbariga M, Curnis F, Andolfo A et al (2015) Ceruloplasmin functional changes in Parkinson\u2019s disease-cerebrospinal fluid. Mol Neurodegeneration 10:59. https:\/\/doi.org\/10.1186\/s13024-015-0055-2","journal-title":"Mol Neurodegeneration"},{"key":"2138_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jnc.13425","volume":"139","author":"AA Belaidi","year":"2016","unstructured":"Belaidi AA, Bush AI (2016) Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: targets for therapeutics. J Neurochem 139:179\u2013197. https:\/\/doi.org\/10.1111\/jnc.13425","journal-title":"J Neurochem"},{"key":"2138_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/archneur.59.6.999","volume":"59","author":"D Berg","year":"2002","unstructured":"Berg D, Roggendorf W, Schr\u00f6der U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999. https:\/\/doi.org\/10.1001\/archneur.59.6.999","journal-title":"Arch Neurol"},{"key":"2138_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03033302","volume":"9","author":"D Berg","year":"2006","unstructured":"Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinson\u2019s disease ultrasonography as a biomarker. Neurotox res 9:1\u201313. https:\/\/doi.org\/10.1007\/BF03033302","journal-title":"Neurotox res"},{"key":"2138_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.parkreldis.2013.08.011","volume":"19","author":"N Bunzeck","year":"2013","unstructured":"Bunzeck N, Singh-Curry V, Eckart C et al (2013) Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson\u2019s disease. Parkinsonism Relat Disord 19:1136\u20131142. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.08.011","journal-title":"Parkinsonism Relat Disord"},{"key":"2138_CR11","doi-asserted-by":"publisher","first-page":"29542","DOI":"10.1074\/jbc.M115.691592","volume":"290","author":"B Butler","year":"2015","unstructured":"Butler B, Saha K, Rana T et al (2015) Dopamine transporter activity is modulated by \u03b1-synuclein. J Biol Chem 290:29542\u201329554. https:\/\/doi.org\/10.1074\/jbc.M115.691592","journal-title":"J Biol Chem"},{"key":"2138_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00167","author":"ZI Cabantchik","year":"2013","unstructured":"Cabantchik ZI, Munnich A, Youdim MB, Devos D (2013) Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2013.00167","journal-title":"Front Pharmacol"},{"key":"2138_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1179\/1743132814Y.0000000443","volume":"37","author":"M Cai","year":"2015","unstructured":"Cai M, Lee K-W, Choi S-M, Yang EJ (2015) TDP-43 modification in the hSOD1 G93A amyotrophic lateral sclerosis mouse model. Neurol Res 37:253\u2013262. https:\/\/doi.org\/10.1179\/1743132814Y.0000000443","journal-title":"Neurol Res"},{"key":"2138_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12017-017-8447-9","volume":"19","author":"E Carboni","year":"2017","unstructured":"Carboni E, Tatenhorst L, T\u00f6nges L et al (2017) deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation. NeuroMol Med 19:309\u2013321. https:\/\/doi.org\/10.1007\/s12017-017-8447-9","journal-title":"NeuroMol Med"},{"key":"2138_CR15","doi-asserted-by":"publisher","first-page":"28097","DOI":"10.1074\/jbc.M115.680090","volume":"290","author":"L Chen","year":"2015","unstructured":"Chen L, Hambright WS, Na R, Ran Q (2015) Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem 290:28097\u201328106. https:\/\/doi.org\/10.1074\/jbc.M115.680090","journal-title":"J Biol Chem"},{"key":"2138_CR16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/emboj.2011.471","volume":"31","author":"TJ Cohen","year":"2012","unstructured":"Cohen TJ, Hwang AW, Unger T et al (2012) Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking: oxidative stress regulates TDP-43. EMBO J 31:1241\u20131252. https:\/\/doi.org\/10.1038\/emboj.2011.471","journal-title":"EMBO J"},{"key":"2138_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/prca.200780081","volume":"2","author":"A Conti","year":"2008","unstructured":"Conti A, Iannaccone S, Sferrazza B et al (2008) Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Prot Clin Appl 2:1628\u20131637. https:\/\/doi.org\/10.1002\/prca.200780081","journal-title":"Prot Clin Appl"},{"key":"2138_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal 21:195\u2013210. https:\/\/doi.org\/10.1089\/ars.2013.5593","journal-title":"Antioxid Redox Signal"},{"key":"2138_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","journal-title":"Cell"},{"key":"2138_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/iub.1616","volume":"69","author":"S Doll","year":"2017","unstructured":"Doll S, Conrad M (2017) Iron and ferroptosis: a still ill-defined liaison: iron and ferroptosis. IUBMB Life 69:423\u2013434. https:\/\/doi.org\/10.1002\/iub.1616","journal-title":"IUBMB Life"},{"key":"2138_CR85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nbd.2016.05.011","volume":"94","author":"B DoVan","year":"2016","unstructured":"DoVan B, Gouel F, Jonneaux A et al (2016) Ferroptosis, a newly characterized form of cell death in Parkinson\u2019s disease that is regulated by PKC. Neurobiol Dis 94:169\u2013178. https:\/\/doi.org\/10.1016\/j.nbd.2016.05.011","journal-title":"Neurobiol Dis"},{"key":"2138_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cell.2010.08.014","volume":"142","author":"JA Duce","year":"2010","unstructured":"Duce JA, Tsatsanis A, Cater MA et al (2010) Iron-export ferroxidase activity of \u03b2-amyloid precursor protein is inhibited by zinc in Alzheimer\u2019s disease. Cell 142:857\u2013867. https:\/\/doi.org\/10.1016\/j.cell.2010.08.014","journal-title":"Cell"},{"key":"2138_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-017-0186-8","volume":"12","author":"JA Duce","year":"2017","unstructured":"Duce JA, Wong BX, Durham H et al (2017) Post translational changes to \u03b1-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson\u2019s disease. Mol Neurodegener 12:45. https:\/\/doi.org\/10.1186\/s13024-017-0186-8","journal-title":"Mol Neurodegener"},{"key":"2138_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0169-328X(01)00242-X","volume":"95","author":"JL Elliott","year":"2001","unstructured":"Elliott JL (2001) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Mol Brain Res 95:172\u2013178. https:\/\/doi.org\/10.1016\/S0169-328X(01)00242-X","journal-title":"Mol Brain Res"},{"key":"2138_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2016.04.035","volume":"624","author":"TM Evans","year":"2016","unstructured":"Evans TM, Bhattacharya A, Shi Y et al (2016) Moderate modulation of disease in the G93A model of ALS by the compound 2-(2-hydroxyphenyl)-benzoxazole (HBX). Neurosci Lett 624:1\u20137. https:\/\/doi.org\/10.1016\/j.neulet.2016.04.035","journal-title":"Neurosci Lett"},{"key":"2138_CR25","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1073\/pnas.92.21.9603","volume":"92","author":"BA Faucheux","year":"1995","unstructured":"Faucheux BA, Nillesse N, Damier P et al (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci 92:9603\u20139607. https:\/\/doi.org\/10.1073\/pnas.92.21.9603","journal-title":"Proc Natl Acad Sci"},{"key":"2138_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","volume":"7","author":"DI Finkelstein","year":"2016","unstructured":"Finkelstein DI, Hare DJ, Billings JL et al (2016) Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice. ACS Chem Neurosci 7:119\u2013129. https:\/\/doi.org\/10.1021\/acschemneuro.5b00253","journal-title":"ACS Chem Neurosci"},{"key":"2138_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI, Billings JL, Adlard PA et al (2017) The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun 5:53. https:\/\/doi.org\/10.1186\/s40478-017-0456-2","journal-title":"Acta Neuropathol Commun"},{"key":"2138_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2014.01.013","volume":"81","author":"AE Frakes","year":"2014","unstructured":"Frakes AE, Ferraiuolo L, Haidet-Phillips AM et al (2014) Microglia induce motor neuron death via the classical nf-\u03bab pathway in amyotrophic lateral sclerosis. Neuron 81:1009\u20131023. https:\/\/doi.org\/10.1016\/j.neuron.2014.01.013","journal-title":"Neuron"},{"key":"2138_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B et al (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16:1180\u20131191. https:\/\/doi.org\/10.1038\/ncb3064","journal-title":"Nat Cell Biol"},{"key":"2138_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2015.00082","author":"A Gajowiak","year":"2016","unstructured":"Gajowiak A, Sty\u015b A, Starzy\u0144ski RR et al (2016) Mice overexpressing both non-mutated human SOD1 and mutated SOD1G93A genes: a competent experimental model for studying iron metabolism in amyotrophic lateral sclerosis. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2015.00082","journal-title":"Front Mol Neurosci"},{"key":"2138_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12640-009-9070-9","volume":"17","author":"S Gal","year":"2010","unstructured":"Gal S, Zheng H, Fridkin M, Youdim MBH (2010) Restoration of nigrostriatal dopamine neurons in post-mptp treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17:15\u201327. https:\/\/doi.org\/10.1007\/s12640-009-9070-9","journal-title":"Neurotox Res"},{"key":"2138_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000049024","volume":"9","author":"P Ghezzi","year":"2001","unstructured":"Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuro Immuno Modul 9:178\u2013182. https:\/\/doi.org\/10.1159\/000049024","journal-title":"Neuro Immuno Modul"},{"key":"2138_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12640-015-9574-4","volume":"29","author":"S Golko-Perez","year":"2016","unstructured":"Golko-Perez S, Mandel S, Amit T et al (2016) Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis. Neurotox Res 29:208\u2013217. https:\/\/doi.org\/10.1007\/s12640-015-9574-4","journal-title":"Neurotox Res"},{"key":"2138_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12640-016-9677-6","volume":"31","author":"S Golko-Perez","year":"2017","unstructured":"Golko-Perez S, Amit T, Bar-Am O et al (2017) A novel iron chelator-radical scavenger ameliorates motor dysfunction and improves life span and mitochondrial biogenesis in SOD1G93A ALS mice. Neurotox Res 31:230\u2013244. https:\/\/doi.org\/10.1007\/s12640-016-9677-6","journal-title":"Neurotox Res"},{"key":"2138_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuint.2017.01.004","volume":"104","author":"SJ Guiney","year":"2017","unstructured":"Guiney SJ, Adlard PA, Bush AI et al (2017) Ferroptosis and cell death mechanisms in Parkinson\u2019s disease. Neurochem Int 104:34\u201348. https:\/\/doi.org\/10.1016\/j.neuint.2017.01.004","journal-title":"Neurochem Int"},{"key":"2138_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman JN, Sanchez-Padilla J, Wokosin D et al (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:696\u2013700. https:\/\/doi.org\/10.1038\/nature09536","journal-title":"Nature"},{"key":"2138_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nmd.2009.08.014","volume":"20","author":"M Halon","year":"2010","unstructured":"Halon M, Sielicka-Dudzin A, Wozniak M et al (2010) Up-regulation of ferritin ubiquitination in skeletal muscle of transgenic rats bearing the G93A hmSOD1 gene mutation. Neuromuscul Disord 20:29\u201333. https:\/\/doi.org\/10.1016\/j.nmd.2009.08.014","journal-title":"Neuromuscul Disord"},{"key":"2138_CR38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3109\/10715762.2014.955484","volume":"48","author":"M Halon","year":"2014","unstructured":"Halon M, Kaczor JJ, Ziolkowski W et al (2014) Changes in skeletal muscle iron metabolism outpace amyotrophic lateral sclerosis onset in transgenic rats bearing the G93A hmSOD1 gene mutation. Free Radic Res 48:1363\u20131370. https:\/\/doi.org\/10.3109\/10715762.2014.955484","journal-title":"Free Radic Res"},{"key":"2138_CR39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/brain\/aww022","volume":"139","author":"DJ Hare","year":"2016","unstructured":"Hare DJ, Double KL (2016) Iron and dopamine: a toxic couple. Brain 139:1026\u20131035. https:\/\/doi.org\/10.1093\/brain\/aww022","journal-title":"Brain"},{"key":"2138_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0969-9961(03)00087-1","volume":"14","author":"K Hensley","year":"2003","unstructured":"Hensley K (2003) Message and protein-level elevation of tumor necrosis factor \u03b1 (TNF\u03b1) and TNF\u03b1-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14:74\u201380. https:\/\/doi.org\/10.1016\/S0969-9961(03)00087-1","journal-title":"Neurobiol Dis"},{"key":"2138_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1471-4159.2002.00968.x","volume":"82","author":"K Hensley","year":"2002","unstructured":"Hensley K, Floyd RA, Gordon B et al (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis: gene expression changes in ALS mice. J Neurochem 82:365\u2013374. https:\/\/doi.org\/10.1046\/j.1471-4159.2002.00968.x","journal-title":"J Neurochem"},{"key":"2138_CR42","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.neuint.2010.09.010","volume":"57","author":"S Higashi","year":"2010","unstructured":"Higashi S, Tsuchiya Y, Araki T et al (2010) TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochem Int 57:906\u2013913. https:\/\/doi.org\/10.1016\/j.neuint.2010.09.010","journal-title":"Neurochem Int"},{"key":"2138_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.expneurol.2018.06.006","volume":"307","author":"JB Hilton","year":"2018","unstructured":"Hilton JB, Kysenius K, White AR, Crouch PJ (2018) The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1G37R mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1. Exp Neurol 307:118\u2013128. https:\/\/doi.org\/10.1016\/j.expneurol.2018.06.006","journal-title":"Exp Neurol"},{"key":"2138_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-3-211-33328-0_21","volume-title":"Oxidative stress and neuroprotection","author":"EC Hirsch","year":"2006","unstructured":"Hirsch EC (2006) Altered regulation of iron transport and storage in Parkinson\u2019s disease. In: Parvez H, Riederer P (eds) Oxidative stress and neuroprotection. Springer, Vienna, pp 201\u2013204"},{"key":"2138_CR45","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1096\/fj.04-3486fje","volume":"19","author":"H Hochstrasser","year":"2005","unstructured":"Hochstrasser H, Tomiuk J, Walter U et al (2005) Functional relevance of ceruloplasmin mutations in Parkinson\u2019s disease. FASEB J 19:1851\u20131853. https:\/\/doi.org\/10.1096\/fj.04-3486fje","journal-title":"FASEB J"},{"key":"2138_CR46","doi-asserted-by":"publisher","first-page":"e0147947","DOI":"10.1371\/journal.pone.0147947","volume":"11","author":"L Hopes","year":"2016","unstructured":"Hopes L, Grolez G, Moreau C et al (2016) Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson\u2019s disease stages? plos One 11:e0147947. https:\/\/doi.org\/10.1371\/journal.pone.0147947","journal-title":"plos One"},{"key":"2138_CR47","doi-asserted-by":"publisher","first-page":"e87119","DOI":"10.1371\/journal.pone.0087119","volume":"9","author":"J Howitt","year":"2014","unstructured":"Howitt J, Gysbers AM, Ayton S et al (2014) Increased Ndfip1 in the substantia nigra of Parkinsonian brains is associated with elevated iron levels. PLoS One 9:e87119. https:\/\/doi.org\/10.1371\/journal.pone.0087119","journal-title":"PLoS One"},{"key":"2138_CR48","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1002\/hbm.23547","volume":"38","author":"DE Huddleston","year":"2017","unstructured":"Huddleston DE, Langley J, Sedlacik J et al (2017) In vivo detection of lateral-ventral tier nigral degeneration in Parkinson\u2019s disease: MRI of Lateral-Ventral SNc in PD. Hum Brain Mapp 38:2627\u20132634. https:\/\/doi.org\/10.1002\/hbm.23547","journal-title":"Hum Brain Mapp"},{"key":"2138_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/17482968.2012.665929","volume":"13","author":"A Ignjatovi\u0107","year":"2012","unstructured":"Ignjatovi\u0107 A, Stevi\u0107 Z, Lavrni\u0107 D et al (2012) Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler 13:357\u2013362. https:\/\/doi.org\/10.3109\/17482968.2012.665929","journal-title":"Amyotroph Lateral Scler"},{"key":"2138_CR50","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/jmri.24121","volume":"38","author":"A Ignjatovi\u0107","year":"2013","unstructured":"Ignjatovi\u0107 A, Stevi\u0107 Z, Lavrni\u0107 S et al (2013) Brain iron MRI: a biomarker for amyotrophic lateral sclerosis brain iron MRI: a biomarker for ALS. J Magn Reson Imaging 38:1472\u20131479. https:\/\/doi.org\/10.1002\/jmri.24121","journal-title":"J Magn Reson Imaging"},{"key":"2138_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ana.410330214","volume":"33","author":"K Ishikawa","year":"1993","unstructured":"Ishikawa K, Nagura H, Yokota T, Yamanouchi H (1993) Signal loss in the motor cortex on magnetic resonance images in amyotrophic lateral sclerosis. Ann Neurol 33:218\u2013222. https:\/\/doi.org\/10.1002\/ana.410330214","journal-title":"Ann Neurol"},{"key":"2138_CR52","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s12035-018-1218-2","volume":"56","author":"GS Jeon","year":"2019","unstructured":"Jeon GS, Shim Y-M, Lee D-Y et al (2019) Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol Neurobiol 56:2007\u20132021. https:\/\/doi.org\/10.1007\/s12035-018-1218-2","journal-title":"Mol Neurobiol"},{"key":"2138_CR53","doi-asserted-by":"publisher","first-page":"9810","DOI":"10.1523\/JNEUROSCI.2922-06.2006","volume":"26","author":"SY Jeong","year":"2006","unstructured":"Jeong SY (2006) Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J Neurosci 26:9810\u20139819. https:\/\/doi.org\/10.1523\/JNEUROSCI.2922-06.2006","journal-title":"J Neurosci"},{"key":"2138_CR54","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1523\/JNEUROSCI.5443-08.2009","volume":"29","author":"SY Jeong","year":"2009","unstructured":"Jeong SY, Rathore KI, Schulz K et al (2009) Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci 29:610\u2013619. https:\/\/doi.org\/10.1523\/JNEUROSCI.5443-08.2009","journal-title":"J Neurosci"},{"key":"2138_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","volume":"37","author":"D Kaur","year":"2003","unstructured":"Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo. Neuron 37:899\u2013909. https:\/\/doi.org\/10.1016\/S0896-6273(03)00126-0","journal-title":"Neuron"},{"key":"2138_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cis.2013.05.003","volume":"197\u2013198","author":"SN Khadzhiev","year":"2013","unstructured":"Khadzhiev SN, Kadiev KM, Yampolskaya GP, Kadieva MKh (2013) Trends in the synthesis of metal oxide nanoparticles through reverse microemulsions in hydrocarbon media. Adv Coll Interface Sci 197\u2013198:132\u2013145. https:\/\/doi.org\/10.1016\/j.cis.2013.05.003","journal-title":"Adv Coll Interface Sci"},{"key":"2138_CR57","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1096\/fj.09-130047","volume":"23","author":"L Kupershmidt","year":"2009","unstructured":"Kupershmidt L, Weinreb O, Amit T et al (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23:3766\u20133779. https:\/\/doi.org\/10.1096\/fj.09-130047","journal-title":"FASEB J"},{"key":"2138_CR58","doi-asserted-by":"publisher","first-page":"e35241","DOI":"10.1371\/journal.pone.0035241","volume":"7","author":"JY Kwan","year":"2012","unstructured":"Kwan JY, Jeong SY, Van Gelderen P et al (2012) Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: CORRELATING 7 Tesla MRI and pathology. PLoS One 7:e35241. https:\/\/doi.org\/10.1371\/journal.pone.0035241","journal-title":"PLoS One"},{"key":"2138_CR59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mds.26883","volume":"32","author":"J Langley","year":"2017","unstructured":"Langley J, Huddleston DE, Sedlacik J et al (2017) Parkinson\u2019s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta: SNpc Hypointensity. Mov Disord 32:441\u2013449. https:\/\/doi.org\/10.1002\/mds.26883","journal-title":"Mov Disord"},{"key":"2138_CR60","doi-asserted-by":"publisher","first-page":"29065","DOI":"10.1074\/jbc.M109.000638","volume":"284","author":"DW Lee","year":"2009","unstructured":"Lee DW, Rajagopalan S, Siddiq A et al (2009) Inhibition of prolyl hydroxylase protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284:29065\u201329076. https:\/\/doi.org\/10.1074\/jbc.M109.000638","journal-title":"J Biol Chem"},{"key":"2138_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.2613","volume":"18","author":"P Lei","year":"2012","unstructured":"Lei P, Ayton S, Finkelstein DI et al (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18:291\u2013295. https:\/\/doi.org\/10.1038\/nm.2613","journal-title":"Nat Med"},{"key":"2138_CR62","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.nbd.2015.03.015","volume":"81","author":"P Lei","year":"2015","unstructured":"Lei P, Ayton S, Appukuttan AT et al (2015) Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 81:168\u2013175. https:\/\/doi.org\/10.1016\/j.nbd.2015.03.015","journal-title":"Neurobiol Dis"},{"key":"2138_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0006-8993(94)90202-X","volume":"650","author":"B Leveugle","year":"1994","unstructured":"Leveugle B, Spik G, Perl DP et al (1994) The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650:20\u201331. https:\/\/doi.org\/10.1016\/0006-8993(94)90202-X","journal-title":"Brain Res"},{"key":"2138_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4236\/nm.2016.71003","volume":"07","author":"AM Lu","year":"2016","unstructured":"Lu AM, Rajanala S, Mikkilineni SV et al (2016) The 5\u2032-Untranslated Region of the C9orf72 mRNA Exhibits a Phylogenetic Alignment to the Cis-Aconitase Iron-Responsive Element; novel therapies for amytrophic lateral sclerosis. Novel 07:15\u201326. https:\/\/doi.org\/10.4236\/nm.2016.71003","journal-title":"Novel"},{"key":"2138_CR65","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/mds.26932","volume":"32","author":"P Mahlknecht","year":"2017","unstructured":"Mahlknecht P, Krismer F, Poewe W, Seppi K (2017) Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson\u2019s disease: DNH on MRI as a Marker for PD. Mov Disord 32:619\u2013623. https:\/\/doi.org\/10.1002\/mds.26932","journal-title":"Mov Disord"},{"key":"2138_CR66","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep 7:1398. https:\/\/doi.org\/10.1038\/s41598-017-01402-2","journal-title":"Sci Rep"},{"key":"2138_CR67","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1073\/pnas.1519473113","volume":"113","author":"P Matak","year":"2016","unstructured":"Matak P, Matak A, Moustafa S et al (2016) Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc Natl Acad Sci USA 113:3428\u20133435. https:\/\/doi.org\/10.1073\/pnas.1519473113","journal-title":"Proc Natl Acad Sci USA"},{"key":"2138_CR68","doi-asserted-by":"publisher","unstructured":"McCarthy RC, Park Y, Kosman DJ (2014) sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep 15:809\u2013815. https:\/\/doi.org\/10.15252\/embr.201338064","DOI":"10.15252\/embr.201338064"},{"key":"2138_CR69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1478-811X-11-34","volume":"11","author":"J Meiser","year":"2013","unstructured":"Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11:34. https:\/\/doi.org\/10.1186\/1478-811X-11-34","journal-title":"Cell Commun Signal"},{"key":"2138_CR70","doi-asserted-by":"publisher","unstructured":"Moreau C, Danel V, Devedjian JC, et al (2018) Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?\u00a9 Caroline Moreau et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Antioxid Redox Signal 29:742\u2013748. https:\/\/doi.org\/10.1089\/ars.2017.7493","DOI":"10.1089\/ars.2017.7493"},{"key":"2138_CR71","doi-asserted-by":"publisher","first-page":"e45034","DOI":"10.1371\/journal.pone.0045034","volume":"7","author":"Y Nadjar","year":"2012","unstructured":"Nadjar Y, Gordon P, Corcia P et al (2012) Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One 7:e45034. https:\/\/doi.org\/10.1371\/journal.pone.0045034","journal-title":"PLoS One"},{"key":"2138_CR72","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jmri.25553","volume":"46","author":"Y Nam","year":"2017","unstructured":"Nam Y, Gho S-M, Kim D-H et al (2017) Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI): nigrosome 1 Imaging Using SMWI. J Magn Reson Imaging 46:528\u2013536. https:\/\/doi.org\/10.1002\/jmri.25553","journal-title":"J Magn Reson Imaging"},{"key":"2138_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/ph11040109","volume":"11","author":"M Nu\u00f1ez","year":"2018","unstructured":"Nu\u00f1ez M, Chana-Cuevas P (2018) New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. Pharmaceuticals 11:109. https:\/\/doi.org\/10.3390\/ph11040109","journal-title":"Pharmaceuticals"},{"key":"2138_CR74","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1148\/radiology.189.3.8234713","volume":"189","author":"H Oba","year":"1993","unstructured":"Oba H, Araki T, Ohtomo K et al (1993) Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 189:843\u2013846. https:\/\/doi.org\/10.1148\/radiology.189.3.8234713","journal-title":"Radiology"},{"key":"2138_CR75","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/157340708786305952","volume":"4","author":"C Perez","year":"2008","unstructured":"Perez C, Tong Y, Guo M (2008) Iron chelators as potential therapeutic agents for parkinsons disease. CBC 4:150\u2013158. https:\/\/doi.org\/10.2174\/157340708786305952","journal-title":"CBC"},{"key":"2138_CR76","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1523\/JNEUROSCI.3117-15.2016","volume":"36","author":"S Rajagopalan","year":"2016","unstructured":"Rajagopalan S, Rane A, Chinta SJ, Andersen JK (2016) Regulation of ATP13A2 via PHD2-HIF1 signaling is critical for cellular iron homeostasis: implications for Parkinson\u2019s disease. J Neurosci 36:1086\u20131095. https:\/\/doi.org\/10.1523\/JNEUROSCI.3117-15.2016","journal-title":"J Neurosci"},{"key":"2138_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jtemb.2013.08.001","volume":"28","author":"P Ramos","year":"2014","unstructured":"Ramos P, Santos A, Pinto NR et al (2014) Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 28:13\u201317. https:\/\/doi.org\/10.1016\/j.jtemb.2013.08.001","journal-title":"J Trace Elem Med Biol"},{"key":"2138_CR78","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2013.09.019","volume":"62","author":"SL Rhodes","year":"2014","unstructured":"Rhodes SL, Buchanan DD, Ahmed I et al (2014) Pooled analysis of iron-related genes in Parkinson\u2019s disease: association with transferrin. Neurobiol Dis 62:172\u2013178. https:\/\/doi.org\/10.1016\/j.nbd.2013.09.019","journal-title":"Neurobiol Dis"},{"key":"2138_CR79","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.acra.2013.09.018","volume":"21","author":"ME Rossi","year":"2014","unstructured":"Rossi ME, Ruottinen H, Saunam\u00e4ki T et al (2014) Imaging brain iron and diffusion patterns. Acad Radiol 21:64\u201371. https:\/\/doi.org\/10.1016\/j.acra.2013.09.018","journal-title":"Acad Radiol"},{"key":"2138_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27947","author":"G Sian","year":"2019","unstructured":"Sian G, Hare D, Double K (2019) Meta-analysis of copper and iron in Parkinson\u2019s disease brain and biofluids. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27947","journal-title":"Mov Disord"},{"key":"2138_CR81","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jnen\/nlz041","volume":"78","author":"CH Stevens","year":"2019","unstructured":"Stevens CH, Guthrie NJ, van Roijen M et al (2019) Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 78:605\u2013614. https:\/\/doi.org\/10.1093\/jnen\/nlz041","journal-title":"J Neuropathol Exp Neurol"},{"key":"2138_CR82","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1042\/BJ20150658","volume":"473","author":"S Torii","year":"2016","unstructured":"Torii S, Shintoku R, Kubota C et al (2016) An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem J 473:769\u2013777. https:\/\/doi.org\/10.1042\/BJ20150658","journal-title":"Biochem J"},{"key":"2138_CR83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fnmol.2018.00131","volume":"11","author":"A Trostchansky","year":"2018","unstructured":"Trostchansky A, Mastrogiovanni M, Miquel E et al (2018) Profile of arachidonic acid-derived inflammatory markers and its modulation by nitro-oleic acid in an inherited model of amyotrophic lateral sclerosis. Front Mol Neurosci 11:131. https:\/\/doi.org\/10.3389\/fnmol.2018.00131","journal-title":"Front Mol Neurosci"},{"key":"2138_CR84","doi-asserted-by":"publisher","first-page":"e57904","DOI":"10.1371\/journal.pone.0057904","volume":"8","author":"M Ulla","year":"2013","unstructured":"Ulla M, Bonny JM, Ouchchane L et al (2013) Is R2* a new MRI biomarker for the progression of Parkinson\u2019s disease? A Longitudinal Follow-Up. PLoS ONE 8:e57904. https:\/\/doi.org\/10.1371\/journal.pone.0057904","journal-title":"A Longitudinal Follow-Up. PLoS ONE"},{"key":"2138_CR86","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ane.12863","volume":"137","author":"JF V\u00e1zquez-Costa","year":"2018","unstructured":"V\u00e1zquez-Costa JF, Maz\u00f3n M, Carreres-Polo J et al (2018) Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis. Acta Neurol Scand 137:262\u2013271. https:\/\/doi.org\/10.1111\/ane.12863","journal-title":"Acta Neurol Scand"},{"key":"2138_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/485723","volume":"2014","author":"C Veyrat-Durebex","year":"2014","unstructured":"Veyrat-Durebex C, Corcia P, Mucha A et al (2014) Iron metabolism disturbance in a french cohort of ALS patients. Biomed Res Int 2014:1\u20136. https:\/\/doi.org\/10.1155\/2014\/485723","journal-title":"Biomed Res Int"},{"key":"2138_CR88","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1111\/j.1460-9568.2007.05515.x","volume":"25","author":"J Wang","year":"2007","unstructured":"Wang J, Jiang H, Xie J-X (2007) Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats: nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 25:2766\u20132772. https:\/\/doi.org\/10.1111\/j.1460-9568.2007.05515.x","journal-title":"Eur J Neurosci"},{"key":"2138_CR89","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000323469","volume":"8","author":"Q Wang","year":"2011","unstructured":"Wang Q, Zhang X, Chen S et al (2011) Prevention of motor neuron degeneration by novel iron chelators in SOD1G93A transgenic mice of amyotrophic lateral sclerosis. Neurodegener Dis 8:310\u2013321. https:\/\/doi.org\/10.1159\/000323469","journal-title":"Neurodegener Dis"},{"key":"2138_CR90","doi-asserted-by":"publisher","first-page":"36669","DOI":"10.1038\/srep36669","volume":"6","author":"J-Y Wang","year":"2016","unstructured":"Wang J-Y, Zhuang Q-Q, Zhu L-B et al (2016) Meta-analysis of brain iron levels of Parkinson\u2019s disease patients determined by postmortem and MRI measurements. Sci Rep 6:36669. https:\/\/doi.org\/10.1038\/srep36669","journal-title":"Sci Rep"},{"key":"2138_CR91","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/jmri.25693","volume":"46","author":"Y Wang","year":"2017","unstructured":"Wang Y, Spincemaille P, Liu Z et al (2017) Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care: Clinical QSM biometals. J Magn Reson Imaging 46:951\u2013971. https:\/\/doi.org\/10.1002\/jmri.25693","journal-title":"J Magn Reson Imaging"},{"key":"2138_CR92","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH et al (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13:1045\u20131060. https:\/\/doi.org\/10.1016\/S1474-4422(14)70117-6","journal-title":"Lancet Neurol"},{"key":"2138_CR93","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","volume":"62","author":"O Weinreb","year":"2013","unstructured":"Weinreb O, Mandel S, Youdim MBH, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson\u2019s disease by iron chelators. Free Radical Biol Med 62:52\u201364. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.01.017","journal-title":"Free Radical Biol Med"},{"key":"2138_CR94","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.spen.2006.08.008","volume":"13","author":"M Whitnall","year":"2006","unstructured":"Whitnall M, Richardson DR (2006) Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13:186\u2013197. https:\/\/doi.org\/10.1016\/j.spen.2006.08.008","journal-title":"Semin Pediatr Neurol"},{"key":"2138_CR95","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1074\/jbc.M117.777201","volume":"292","author":"JD Wofford","year":"2017","unstructured":"Wofford JD, Chakrabarti M, Lindahl PA (2017) M\u00f6ssbauer spectra of mouse hearts reveal age-dependent changes in mitochondrial and ferritin iron levels. J Biol Chem 292:5546\u20135554. https:\/\/doi.org\/10.1074\/jbc.M117.777201","journal-title":"J Biol Chem"},{"key":"2138_CR96","doi-asserted-by":"publisher","first-page":"e114174","DOI":"10.1371\/journal.pone.0114174","volume":"9","author":"BX Wong","year":"2014","unstructured":"Wong BX, Tsatsanis A, Lim LQ et al (2014) \u03b2-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 9:e114174. https:\/\/doi.org\/10.1371\/journal.pone.0114174","journal-title":"PLoS One"},{"key":"2138_CR97","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1039\/C4MT00326H","volume":"7","author":"DG Workman","year":"2015","unstructured":"Workman DG, Tsatsanis A, Lewis FW et al (2015) Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson\u2019s with novel 1-hydroxypyridin-2-one metal chelators. Metallomics 7:867\u2013876. https:\/\/doi.org\/10.1039\/C4MT00326H","journal-title":"Metallomics"},{"key":"2138_CR98","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nbd.2017.05.001","volume":"104","author":"K-C Wu","year":"2017","unstructured":"Wu K-C, Liou H-H, Kao Y-H et al (2017) The critical role of Nramp1 in degrading \u03b1-synuclein oligomers in microglia under iron overload condition. Neurobiol Dis 104:61\u201372. https:\/\/doi.org\/10.1016\/j.nbd.2017.05.001","journal-title":"Neurobiol Dis"},{"key":"2138_CR99","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuroscience.2014.09.071","volume":"284","author":"L-H You","year":"2015","unstructured":"You L-H, Li F, Wang L et al (2015) Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson\u2019s disease. Neuroscience 284:234\u2013246. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.09.071","journal-title":"Neuroscience"},{"key":"2138_CR100","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.mad.2004.08.023","volume":"126","author":"MBH Youdim","year":"2005","unstructured":"Youdim MBH, Fridkin M, Zheng H (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126:317\u2013326. https:\/\/doi.org\/10.1016\/j.mad.2004.08.023","journal-title":"Mech Ageing Dev"},{"key":"2138_CR101","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/mds.20550","volume":"20","author":"L Zecca","year":"2005","unstructured":"Zecca L, Berg D, Arzberger T et al (2005) In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20:1278\u20131285. https:\/\/doi.org\/10.1002\/mds.20550","journal-title":"Mov Disord"},{"key":"2138_CR102","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s12192-017-0804-y","volume":"22","author":"R Zeineddine","year":"2017","unstructured":"Zeineddine R, Farrawell NE, Lambert-Smith IA, Yerbury JJ (2017) Addition of exogenous SOD1 aggregates causes TDP-43 mislocalisation and aggregation. Cell Stress Chaperones 22:893\u2013902. https:\/\/doi.org\/10.1007\/s12192-017-0804-y","journal-title":"Cell Stress Chaperones"},{"key":"2138_CR103","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuroscience.2013.09.037","volume":"257","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Hou L, Song J-L et al (2014) Pro-inflammatory cytokine-mediated ferroportin down-regulation contributes to the nigral iron accumulation in lipopolysaccharide-induced Parkinsonian models. Neuroscience 257:20\u201330. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.09.037","journal-title":"Neuroscience"},{"key":"2138_CR104","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.parkreldis.2017.01.003","volume":"36","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Wang B, Tao K et al (2017) Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson\u2019s disease. Parkinsonism Relat Disord 36:76\u201382. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.01.003","journal-title":"Parkinsonism Relat Disord"},{"key":"2138_CR105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","volume":"155","author":"FA Zucca","year":"2017","unstructured":"Zucca FA, Segura-Aguilar J, Ferrari E et al (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol 155:96\u2013119. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.09.012","journal-title":"Prog Neurobiol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02138-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02138-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02138-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T01:25:15Z","timestamp":1609896315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02138-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02138-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial disclosures to make or potential conflicts of interest to report in relation to this study. The paper is referring to four academic studies including two translational studies already published : FAIRPARK-I (Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease Protocol ID: 2008-006842-25; ClinicalTrials.gov: NCT00943748) and SAFEFAIR-ALS (Efficacy and Safety of the Iron Chelator Deferiprone in Amyotrophic lateral sclerosis Protocol ID: 2013-001228-21; ClinicalTrials.gov: NCT02164253) and two in progress : FAIRPARK-II (with the French NS-Park network, which is funded by a grant from the European Commission Horizon 2020 PHC13 2014-2015 (N\u00b0 633190): \u201cConservative iron chelation as a disease-modifying strategy in Parkinson\u2019s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone\u201d Protocol ID: 2015_22; Clinical trial: NCT02655315 http:\/\/fairpark2.eu) and FAIRALS-II (Conservative Iron Chelation by Deferiprone as a Disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial on 240 patients. Protocol ID: 2017-003763-35; ClinicalTrials.gov: NCT03293069 funded by the French Ministry of Health, PHRC-N2017). ApoPharma provided deferiprone and advices on the molecule for the four investigator drive studies.\nCaroline Moreau has received grants from the France Parkinson charity. She has received various honoraria from pharmaceutical companies for consultancy and lectures on Parkinson\u2019s disease at symposia such as Aguettant, Abbvie, Medtronic, Novartis. James Duce has received research funding from Alzheimer\u2019s Society, Alzheimer\u2019s Research UK, European Commission, Parkinson\u2019s UK and NHMRC. He serves as a scientific advisor on the FAIRPARK II but has no financial disclosures. Ioav Cabantchik consults for Aferrix Ltd (Israel) and Hinoman (Ltd) Israel and has been an invited speaker in meetings organized by Apopharma (Canada) for which he received lecturer honoraria. David Devos has received PHRC grants from the French Ministry of Health and research funding from the ARSLA charity, France Parkinson charity, Credit Agricole Fundation. He has led two pilot investigator driven studies with DFP provided for free by ApoPharma (FAIRPARK-I and SAFE-FAIR ALS-I). He is leading two large investigator driven studies with DFP provided for free by ApoPharma (FAIRPARK-II and FAIR ALS-II). He served on advisory boards, served as a consultant and given lectures for pharmaceutical companies such as Orkyn, Everpharma, Abbvie, Boston Scientific, Lundbeck. Jean-Christophe Devedjian, V\u00e9ronique Danel, Laura Mahoney-Sanchez, Hind Bouchaoui, Anne-Sophie Rolland have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}